C4 Therapeutics Presents Promising Phase 1 Data for Cemsidomide in Multiple Myeloma
C4 Therapeutics, Inc. announced the presentation of updated Phase 1 data for its investigational drug cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association (EHA) 2026 Congress. The data, with a cutoff of February 27, 2026, showed a 53% overall response rate (ORR) at the recommended Phase 2 dose (RP2D) of 100 µg, with responses deepening over time and some achieving stringent complete response (sCR) and minimal residual disease (MRD) negativity. The combination was generally well-tolerated. The company is advancing cemsidomide through further clinical trials, including the Phase 2 MOMENTUM trial in 4L+ MM and a Phase 1b trial with elranatamab, and is also exploring a new discovery strategy in INN diseases.
Key Highlights
- C4 Therapeutics presented Phase 1 data for cemsidomide + dexamethasone at EHA 2026 Congress.
- At the 100 µg RP2D, cemsidomide showed a 53% ORR in heavily pretreated RRMM patients.
- Responses deepened over time, with some patients achieving sCR and MRD negativity.
- Cemsidomide was well-tolerated with minimal dose reductions or discontinuations.
- Phase 2 MOMENTUM trial for cemsidomide in 4L+ MM is enrolling, with data expected in 2H 2027.
- Phase 1b trial combining cemsidomide with elranatamab is ongoing, with data expected mid-2027.
- Company is also advancing a new discovery strategy focused on Inflammation, Neuroinflammation, & Neurodegeneration (INN) diseases.
Price Impact
More from CCCC